Abstract
Herbal therapeutics offer substantial pharmacological potential, yet their translation into clinically reliable phytopharmaceutical products remains constrained by poor aqueous solubility, low and variable bioavailability, chemical instability, batch-to-batch phytochemical variation, limited pharmacokinetic predictability and insufficient site-specific delivery.This structured narrative review examines how artificial intelligence (AI) can guide the rational development of herbal drug delivery systems.Peer-reviewed literature was identified through targeted, iterative searches of PubMed and major publisher platforms, supplemented by backward reference tracking and authoritative regulatory documents.Searches covered January 2010 to 20 June 2026; earlier landmark studies were retained when foundational to formulation optimization, controlled release or phytochemical delivery.Evidence was organized across four linked methodological layers: machine-learning and deep-learning approaches for phytochemical prioritization; prediction of physicochemical, pharmacokinetic, toxicity and drug-carrier interaction profiles; AI-assisted optimization of phytosomes, liposomes, polymeric nanoparticles, nanocrystals, lipid carriers, nanoemulsions and hydrogels; and future adaptive systems supported by explainable AI, digital twins, reinforcement learning and digital health data.The synthesis shows that AI can reduce experimental burden, expose nonlinear formulation relationships and support multi-objective decisions involving particle attributes, loading, release, stability, manufacturability and safety.However, direct studies integrating AI with herbal delivery remain limited; much of the current rationale is built by connecting mature evidence from natural-product delivery with rapidly advancing AI-enabled pharmaceutical formulation.A proposed phytochemical-carrier-patient digital thread is therefore introduced to preserve traceability from botanical batch identity to product quality, biological disposition and patient context.Translation will require standardized phytochemical datasets, external and prospective validation, uncertainty reporting, explainable and change-controlled models, quality-by-design integration and clinically meaningful performance benchmarks.AI-driven herbal drug delivery should consequently be viewed not as an automated replacement for experimentation, but as a transparent decision-support system capable of moving phytopharmaceutical development from empirical screening toward predictive, adaptive and precision-oriented design.